Ampio Pharmaceutical (AMPE) 6.03 $AMPE
Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion(TM) in the new facility.
PR Newswire - Wed Jul 30, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a positive written response from the FDA in regards to the company's plans to begin production of AmpionTM in our new drug manufacturing facility.
Buying the Dips and Selling the Rips Is the New Norm for This Market
at The Street - Tue Jul 29, 4:28PM CDT
The stock market continues to make wild intraday swings and traders need to be extremely careful.
How Many More 100-Point-Swing Days on the DJIA Can You Take?
at The Street - Mon Jul 28, 4:43PM CDT
The stock indexes fluctuated wildly on Monday as the hedge funds trading the S&P between the daily trading range.
Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado
PR Newswire - Wed Jul 23, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the opening of its new headquarters, manufacturing and research facility:
Ampio Initiates Study of Multiple Injections of Ampion(TM) Into the Knees of Patients with OA of the Knee to Assess its Healing and Cartilage Regeneration Effects
PR Newswire - Mon Jun 30, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has started patient enrollment for the MULTIPLE INJECTIONS STUDY using AmpionTM for patients with mostly severe or very severe osteoarthritis (mostly severe Kellgren-Lawrence grade 3 and 4) of the knee for which there is no current non-surgical therapy.
Ampio Expects Investors to Wear Beer Goggles Before Reading Eye-Drug Press Release
at The Street - Wed Jun 25, 12:05PM CDT
The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.
Ampio Pharmaceuticals, in Response to Positive Feedback, Closes Enrollment in the OptimEyes Study (Optina(TM)) and Will Present the Data to the FDA for Guidance
PR Newswire - Wed Jun 25, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes Study for the treatment of Diabetic Macular Edema (oral treatment with Optina(TM)). This trial was intended to enroll 450 patients and was powered at 95%. The present enrollment of over 355 patients provides an adequate power of 88%, which the company believes is more than sufficient for statistical evaluation.
Ampio Pharmaceuticals names Gregory A Gould as CFO
M2 - Fri Jun 06, 3:00AM CDT
Biopharmaceutical company Ampio Pharmaceuticals (NYSE MKT: AMPE) reported on Thursday the election of Gregory A Gould as its chief financial officer, treasurer and corporate secretary.
Ampio Pharmaceuticals Announces Appointment of Gregory A. Gould as Chief Financial Officer
PR Newswire - Thu Jun 05, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the appointment of Gregory A. Gould as Chief Financial Officer, Treasurer, and Corporate Secretary. Mr. Gould, a veteran of the pharmaceutical and life sciences industry, is joining the company effective June 10th, 2014. Mark McGregor, the company's current CFO, will retire from Ampio Pharmaceuticals following a transition period later this year.
Diabetic Retinopathy - Pipeline Review, H1 2014: 29 Companies Profiled
M2 - Thu May 29, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pr6rhf/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Acucela Inc. - Ampio Pharmaceuticals - Antisense Therapeutics Limited - BioDiem Ltd - Biomar Microbial Technologies - Bionure Farma, S.L. - CCRP Therapeutics GmbH - Charlesson LLC. - EyeCyte - EyeGene - FirstString Research - Foresee Pharmaceuticals, LLC - Gene Signal International SA - Inotek Pharmaceuticals Corporation - Intercept Pharmaceuticals - Lpath - MingSight Pharmaceuticals - Paloma Pharmaceuticals - PanOptica - Promedior - Protagonist Therapeutics Inc. - Protemix Corporation Limited - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals - Resolvyx Pharmaceuticals, Inc - Stelic Institute & Co. - Targazyme - ThromboGenics NV - Vascular Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/pr6rhf/diabetic
Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
Stroke - Pipeline Review, H1 2014: Includes 62 Company Profiles
M2 - Thu May 29, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4c67qc/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Include: - AGY Therapeutics, Inc. - APT Therapeutics, Inc. - Acorda Therapeutics, Inc. - Ampio Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - Angion Biomedica Corp. - ArmaGen Technologies, Inc. - Aronora, LLC - AstraZeneca PLC - CHA Bio & Diostech Co., Ltd. - CardioVascular BioTherapeutics, Inc. - CoDa Therapeutics, Inc. - Covigilance sro - D-Pharm Ltd. - Diakron Pharmaceuticals, Inc. - Dongwha Pharm Co., Ltd. - Encore Therapeutics Inc. - F. Hoffmann-La Roche Ltd. - Fina Biotech - Generon (Shanghai) Corporation Ltd. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - GliaMed, Inc. - Green Cross Corporation - Huons Co., Ltd. - InVasc Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Jeil Pharmaceutical Co., Ltd. - Kolon Life Science, Inc. For more information visit http://www.researchandmarkets.com/research/4c...e_pipeline
Ampio Pharmaceuticals to present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3rd at 8:30 AM
PR Newswire - Wed May 21, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the Jefferies Global Healthcare Conference in New York City.
Luoxis Obtains CE Marking for RedoxSYS(TM) Diagnostic System
PR Newswire - Wed Apr 02, 7:00AM CDT
Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS(TM) Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in strategic market development activities designed to establish the clinical utility of the RedoxSYS System in the critical care setting, and position the company for a successful launch in Europe, which is currently anticipated for 2015.
Ampio Announces Investor call Thursday March 13, 4 PM EDT.
PR Newswire - Tue Mar 11, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced dial in details for a scheduled investor call, Thursday, March 13, 4:00 PM EDT. Participants are invited to dial in using the instructions as follows:
Ampio Pharmaceuticals, Inc. Closes Sale Of 9,775,000 Shares Of Common Stock
PR Newswire - Wed Mar 05, 9:53AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the closing of its sale of 9,775,000 shares of common stock in an underwritten public offering. The total number of shares of common stock sold reflects the full exercise by the underwriters of their option to purchase an additional 1,275,000 shares of common stock. As a result, Ampio Pharmaceuticals, Inc. has received gross proceeds of approximately $68 million. Net proceeds, after deducting underwriting discounts and commissions and other estimated fees and expenses payable by Ampio Pharmaceuticals, Inc., will be approximately $63.3 million.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 01, 6:00AM CST
Another month in 2014 has drawn to a close -- as has another week of horrendous performances by several health-care stocks. February is the shortest month of the year, but its final week proved to be quite a long one for some investors. One of this...
Today's Top Biotech Stories: Ampio Pharmaceuticals, Auxilium Pharmaceuticals, Bayer, and Medivation
George Budwell, The Motley Fool - Motley Fool - Fri Feb 28, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Ampio Pharmaceuticals prices public offering at USD7.00 per share
M2 - Fri Feb 28, 3:53AM CST
US-based biopharmaceutical company Ampio Pharmaceuticals (NYSE MKT:AMPE) revealed on Thursday that it has priced its public offering of 8.5m shares of its common stock.
Ampio Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of 8,500,000 Shares Of Common Stock
PR Newswire - Thu Feb 27, 7:01PM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has priced an underwritten public offering of 8,500,000 shares of its common stock. The shares will be sold at a price to the public of $7.00 per share for gross proceeds of $59.5 million.
Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion(TM) in the new facility.
PR Newswire - Wed Jul 30, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a positive written response from the FDA in regards to the company's plans to begin production of AmpionTM in our new drug manufacturing facility.
Buying the Dips and Selling the Rips Is the New Norm for This Market
at The Street - Tue Jul 29, 4:28PM CDT
The stock market continues to make wild intraday swings and traders need to be extremely careful.
How Many More 100-Point-Swing Days on the DJIA Can You Take?
at The Street - Mon Jul 28, 4:43PM CDT
The stock indexes fluctuated wildly on Monday as the hedge funds trading the S&P between the daily trading range.
Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado
PR Newswire - Wed Jul 23, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the opening of its new headquarters, manufacturing and research facility:
Ampio Initiates Study of Multiple Injections of Ampion(TM) Into the Knees of Patients with OA of the Knee to Assess its Healing and Cartilage Regeneration Effects
PR Newswire - Mon Jun 30, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has started patient enrollment for the MULTIPLE INJECTIONS STUDY using AmpionTM for patients with mostly severe or very severe osteoarthritis (mostly severe Kellgren-Lawrence grade 3 and 4) of the knee for which there is no current non-surgical therapy.
Ampio Expects Investors to Wear Beer Goggles Before Reading Eye-Drug Press Release
at The Street - Wed Jun 25, 12:05PM CDT
The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.
Ampio Pharmaceuticals, in Response to Positive Feedback, Closes Enrollment in the OptimEyes Study (Optina(TM)) and Will Present the Data to the FDA for Guidance
PR Newswire - Wed Jun 25, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes Study for the treatment of Diabetic Macular Edema (oral treatment with Optina(TM)). This trial was intended to enroll 450 patients and was powered at 95%. The present enrollment of over 355 patients provides an adequate power of 88%, which the company believes is more than sufficient for statistical evaluation.
Ampio Pharmaceuticals names Gregory A Gould as CFO
M2 - Fri Jun 06, 3:00AM CDT
Biopharmaceutical company Ampio Pharmaceuticals (NYSE MKT: AMPE) reported on Thursday the election of Gregory A Gould as its chief financial officer, treasurer and corporate secretary.
Ampio Pharmaceuticals Announces Appointment of Gregory A. Gould as Chief Financial Officer
PR Newswire - Thu Jun 05, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the appointment of Gregory A. Gould as Chief Financial Officer, Treasurer, and Corporate Secretary. Mr. Gould, a veteran of the pharmaceutical and life sciences industry, is joining the company effective June 10th, 2014. Mark McGregor, the company's current CFO, will retire from Ampio Pharmaceuticals following a transition period later this year.
Diabetic Retinopathy - Pipeline Review, H1 2014: 29 Companies Profiled
M2 - Thu May 29, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pr6rhf/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Acucela Inc. - Ampio Pharmaceuticals - Antisense Therapeutics Limited - BioDiem Ltd - Biomar Microbial Technologies - Bionure Farma, S.L. - CCRP Therapeutics GmbH - Charlesson LLC. - EyeCyte - EyeGene - FirstString Research - Foresee Pharmaceuticals, LLC - Gene Signal International SA - Inotek Pharmaceuticals Corporation - Intercept Pharmaceuticals - Lpath - MingSight Pharmaceuticals - Paloma Pharmaceuticals - PanOptica - Promedior - Protagonist Therapeutics Inc. - Protemix Corporation Limited - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals - Resolvyx Pharmaceuticals, Inc - Stelic Institute & Co. - Targazyme - ThromboGenics NV - Vascular Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/pr6rhf/diabetic
Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
Stroke - Pipeline Review, H1 2014: Includes 62 Company Profiles
M2 - Thu May 29, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4c67qc/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Include: - AGY Therapeutics, Inc. - APT Therapeutics, Inc. - Acorda Therapeutics, Inc. - Ampio Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - Angion Biomedica Corp. - ArmaGen Technologies, Inc. - Aronora, LLC - AstraZeneca PLC - CHA Bio & Diostech Co., Ltd. - CardioVascular BioTherapeutics, Inc. - CoDa Therapeutics, Inc. - Covigilance sro - D-Pharm Ltd. - Diakron Pharmaceuticals, Inc. - Dongwha Pharm Co., Ltd. - Encore Therapeutics Inc. - F. Hoffmann-La Roche Ltd. - Fina Biotech - Generon (Shanghai) Corporation Ltd. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - GliaMed, Inc. - Green Cross Corporation - Huons Co., Ltd. - InVasc Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Jeil Pharmaceutical Co., Ltd. - Kolon Life Science, Inc. For more information visit http://www.researchandmarkets.com/research/4c...e_pipeline
Ampio Pharmaceuticals to present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3rd at 8:30 AM
PR Newswire - Wed May 21, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the Jefferies Global Healthcare Conference in New York City.
Luoxis Obtains CE Marking for RedoxSYS(TM) Diagnostic System
PR Newswire - Wed Apr 02, 7:00AM CDT
Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS(TM) Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in strategic market development activities designed to establish the clinical utility of the RedoxSYS System in the critical care setting, and position the company for a successful launch in Europe, which is currently anticipated for 2015.
Ampio Announces Investor call Thursday March 13, 4 PM EDT.
PR Newswire - Tue Mar 11, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced dial in details for a scheduled investor call, Thursday, March 13, 4:00 PM EDT. Participants are invited to dial in using the instructions as follows:
Ampio Pharmaceuticals, Inc. Closes Sale Of 9,775,000 Shares Of Common Stock
PR Newswire - Wed Mar 05, 9:53AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the closing of its sale of 9,775,000 shares of common stock in an underwritten public offering. The total number of shares of common stock sold reflects the full exercise by the underwriters of their option to purchase an additional 1,275,000 shares of common stock. As a result, Ampio Pharmaceuticals, Inc. has received gross proceeds of approximately $68 million. Net proceeds, after deducting underwriting discounts and commissions and other estimated fees and expenses payable by Ampio Pharmaceuticals, Inc., will be approximately $63.3 million.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 01, 6:00AM CST
Another month in 2014 has drawn to a close -- as has another week of horrendous performances by several health-care stocks. February is the shortest month of the year, but its final week proved to be quite a long one for some investors. One of this...
Today's Top Biotech Stories: Ampio Pharmaceuticals, Auxilium Pharmaceuticals, Bayer, and Medivation
George Budwell, The Motley Fool - Motley Fool - Fri Feb 28, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Ampio Pharmaceuticals prices public offering at USD7.00 per share
M2 - Fri Feb 28, 3:53AM CST
US-based biopharmaceutical company Ampio Pharmaceuticals (NYSE MKT:AMPE) revealed on Thursday that it has priced its public offering of 8.5m shares of its common stock.
Ampio Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of 8,500,000 Shares Of Common Stock
PR Newswire - Thu Feb 27, 7:01PM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has priced an underwritten public offering of 8,500,000 shares of its common stock. The shares will be sold at a price to the public of $7.00 per share for gross proceeds of $59.5 million.
